Movement Alert｜Abivax S.A. Rises 5.48% in Regular Trading, Bull-Bear Debate Intensifies Amid Phase 3 Trial Safety Controversy

Market Focus06-26 22:30

On June 26, Abivax S.A. rose 5.48% in regular trading, trading at $96.87/share, with turnover of $50.50 million.

On the news front, the stock saw a notable intraday rebound as the bull-bear debate over safety concerns surrounding its core drug obefazimod intensified. The company's Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dose group, triggering a sharp selloff that took shares from approximately $130 to around $70 — a decline of nearly 50%. However, some investors have since argued that the cancer cases are more likely age-related rather than drug-related, and that the trial successfully met its primary endpoint, suggesting the initial market reaction was excessive.

The stock had previously rebounded above $100 before retreating again in recent sessions amid persistent safety-related uncertainty. The current intraday bounce reflects renewed buying interest as bulls reassert the overreaction thesis, though the broader market consensus on the drug's safety profile remains unresolved.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164658041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164658041","market":"us","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Rises 5.48% in Regular Trading, Bull-Bear Debate Intensifies Amid Phase 3 Trial Safety Controversy","media":"Market Focus","content":"<p><p>On June 26, Abivax S.A. rose 5.48% in regular trading, trading at $96.87/share, with turnover of $50.50 million.</p><p>On the news front, the stock saw a notable intraday rebound as the bull-bear debate over safety concerns surrounding its core drug obefazimod intensified. The company's Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dose group, triggering a sharp selloff that took shares from approximately $130 to around $70 — a decline of nearly 50%. However, some investors have since argued that the cancer cases are more likely age-related rather than drug-related, and that the trial successfully met its primary endpoint, suggesting the initial market reaction was excessive.</p><p>The stock had previously rebounded above $100 before retreating again in recent sessions amid persistent safety-related uncertainty. The current intraday bounce reflects renewed buying interest as bulls reassert the overreaction thesis, though the broader market consensus on the drug's safety profile remains unresolved.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Rises 5.48% in Regular Trading, Bull-Bear Debate Intensifies Amid Phase 3 Trial Safety Controversy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Rises 5.48% in Regular Trading, Bull-Bear Debate Intensifies Amid Phase 3 Trial Safety Controversy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Abivax S.A. rose 5.48% in regular trading, trading at $96.87/share, with turnover of $50.50 million.</p><p>On the news front, the stock saw a notable intraday rebound as the bull-bear debate over safety concerns surrounding its core drug obefazimod intensified. The company's Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dose group, triggering a sharp selloff that took shares from approximately $130 to around $70 — a decline of nearly 50%. However, some investors have since argued that the cancer cases are more likely age-related rather than drug-related, and that the trial successfully met its primary endpoint, suggesting the initial market reaction was excessive.</p><p>The stock had previously rebounded above $100 before retreating again in recent sessions amid persistent safety-related uncertainty. The current intraday bounce reflects renewed buying interest as bulls reassert the overreaction thesis, though the broader market consensus on the drug's safety profile remains unresolved.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1164658041","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164658041","pubTimestamp":1782484216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Abivax S.A. rose 5.48% in regular trading, trading at $96.87/share, with turnover of $50.50 million.On the news front, the stock saw a notable intraday rebound as the bull-bear debate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"动向提示|Abivax S.A.常规交易涨5.48%3期试验安全性争议下牛熊争论加剧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On June 26, Abivax S.A. rose 5.48% in regular trading, trading at $96.87/share, with turnover of $50.50 million.On the news front, the stock saw a notable intraday rebound as the bull-bear debate over safety concerns surrounding its core drug obefazimod intensified. The company's Phase 3 ABTECT maintenance trial previously reported multiple cancer cases in the 50mg dose group, triggering a sharp selloff that took shares from approximately $130 to around $70 — a decline of nearly 50%. However, some investors have since argued that the cancer cases are more likely age-related rather than drug-related, and that the trial successfully met its primary endpoint, suggesting the initial market reaction was excessive.The stock had previously rebounded above $100 before retreating again in recent sessions amid persistent safety-related uncertainty. The current intraday bounce reflects renewed buying interest as bulls reassert the overreaction thesis, though the broader market consensus on the drug's safety profile remains unresolved.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164658041","isCrawlerRequest":true}